Diskusjon Triggere Porteføljer Aksjonærlister

Nordic Nanovector - Småprat 2020 (NANO)

Biotek
#1319

Husker du hvor mange det var i desember?

#1320

36 ?

#1321

Takk

#1322

De hadde 32 pas i oktober. Mer vet vi ikke

3 Likes
#1323

Bye bye, Bravo. Ikkje bra.

#1324

Interim CEO? Hva skjer her nå?

#1325

LOL

Om ikke bayer skal kjøpe nano er alt fucked

Edit:

@Coiltubing setter her fingeren på nøyaktig det samme som jeg tenker på.

2 Likes
#1326

Oioioi dette virker ikke bra…

#1327

Under 20, here we go. Dette kan ikke love bra

#1328

Ugh. Trodde ikke jeg skulle bli «glad» for at jeg tømte meg for all NANO før jul på kr 27 men det er jeg nå gitt. Sketchy opplegg.

#1329

I hvert fall bra de har kvartalsrapport i morgen så de kan svare på spørsmål rundt det her…

#1331

Hun har ikke endret noe på linkedin i hvert fall.

#1332

Styreformann svarer på spørsmål om CEO. Helt vanlig praksis.

4 Likes
#1333

NANO er vel oppkjøpt av Big Pharma, og Lars Nieba sitter foreløpig til kabalen er lagt! :slight_smile:

#1334

Hvorfor skulle Bravo dra da? Og ikke få på CV’en at han var CEO da NANO ble kjøp opp av “Big Pharma”. Dette virker bekymringsfullt. Håper jeg tar feil.

#1335

Deler ikke helt din optimisme desverre.

#1336

Skjer? Link me up bruh.

De sa jo nettopp på podcast at Bravo muligens kommer på besøk 1 april.

#1337

Tror de er veldig off track, ettersom han trekker seg.

#1338

Nordic Nanovector ASA (OSE: NANO) announces that Dr Lars Nieba has been appointed interim Chief Executive Officer with immediate effect. Dr Nieba, who is currently the Company’s Chief Technology Officer, replaces Eduardo Bravo who as of today has left Nordic Nanovector to pursue other career opportunities.

Dr Nieba joined Nordic Nanovector on 1 December 2019 from Bayer AG where he served in various operational and strategic roles, Dr Nieba was most recently responsible for driving Bayer’s Chemistry, Manufacturing and Controls (CMC) strategy for biologicals. He joined Bayer in 2016 following 13 years at F. Hoffmann-La Roche Ltd., where he held various leadership roles in clinical, operations, supply planning, biologics technology and technical business development. Prior Dr Nieba worked for Cytos Biotechnology where he served as Head of Therapeutic Vaccine Research.

Dr Nieba gained a PhD from the Max-Planck-Institute for Biochemistry, München and Institute for Biochemistry at the University of Zürich, and an Executive MBA from the University of St. Gallen, Switzerland.

Jan H. Egberts, MD, Chairman of Nordic Nanovector, commented: “The Board is very pleased to appoint Lars Nieba as Nordic Nanovector’s interim CEO. We believe that his significant operational, development and product supply expertise will be crucial as we work towards completing the PARADIGME study and prepare for the planned filing for Betalutin® with the FDA. On behalf of the Board I would like to thank Eduardo for his contribution as CEO.”

1 Like
#1339

Det kan kanskje være nærliggende å anta at det skyldes uenighet med styret i en eller annen form.